Answers are grounded in this paper and cite their sources.
Crimean–Congo hemorrhagic fever virus (CCHFV) is a tick-borne pathogen responsible for severe hemorrhagic disease in humans, frequently associated with systemic inflammation and significant hepatic involvement. The S genomic segment encodes the nucleoprotein (NP), a highly constrained component of the viral replication machinery. While the evolutionary dynamics of CCHFV have been studied, the translation of genomic variability into immunopathogenic mechanisms and rational vaccine targets remains incompletely characterized. In this study, we employed a multi-tiered in silico approach, combining comparative genomics of 577 global S segment sequences with comprehensive epitope mapping and molecular docking. Genomic analysis, including Shannon entropy, principal component analysis (PCA), and network modeling, revealed discrete lineage clusters and strictly conserved structural domains. Building upon these conserved regions, immunoinformatics profiling identified 3 highly conserved MHC-I and 4 MHC-II epitopes. Crucially, the lead T-cell epitope (ETFPTVSQF) was identified. Molecular docking analysis against human Toll-like receptor 4 (TLR4) using GalaxyPepDock demonstrated robust binding affinities and high structural compatibility, yielding TM-scores up to 0.780 and interaction similarity scores up to -15.0. Furthermore, C-IMMSIM immunological simulations predicted strong, sustained memory B- and T-cell responses, characterized by robust IFN-γ production and high immunoglobulin titers, ensuring efficient viral clearance profiles. Crucially, in vivo validation in mouse models demonstrated that the adjuvanted ETFPTVSQF peptide drastically reduced hepatic viral loads compared to PBS controls (*** P < 0.001), confirming its protective efficacy against liver injury. Collectively, these findings provide a global genomic perspective on CCHFV S segment diversity and propose structurally conserved, immunogenic candidates that could guide the development of targeted diagnostics and recombinant vaccines mitigating hepatic and systemic injury.
No takes yet. Share an insight, caveat, or question.
Akrami et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: